Montana Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• Cost-Effectiveness of Early TAVR; TR and Mortality; Superiority of Tricuspid Repair
  New late-breaking research presented at TCT 2026 highlights the cost-effectiveness of early TAVR in asymptomatic severe aortic stenosis (AS), the association between increasing tricuspid regurgitation (TR) severity and mortality, and the benefits of transcatheter tricuspid valve repair.
• VERITAS and TRAVEL III: LAAO With Amulet 360; TTVR With LuX-Valve Plus System
  Among patients who underwent left atrial appendage occlusion (LAAO) with the Amulet 360 device, complete LAA closure was observed in 96.3% of patients at one year with low rates of stroke and mortality, according to results from the VERITAS trial, presented at TCT 2026 and simultaneously published in JACC: Cardiovascular Interventions.
• TECTONIC CAD and NODULE-SHOCK: IVL in Patients With Severely Calcified Lesions
  Two separate studies presented at TCT 2026 and simultaneously published in JACC: Cardiovascular Interventions address the safety and effectiveness of intravascular lithotripsy (IVL) in patients with severely calcified lesions.
• REMEDY-PILOT: Coronary Sinus Reducer Shows No Significant Improvement in Patients With CMD and ANOCA
  In patients with coronary microvascular dysfunction (CMD) and refractory angina with nonobstructive coronary arteries (ANOCA), coronary sinus reducer (CSR) implantation did not significantly improve myocardial perfusion reserve (MPR), patient-reported symptoms or quality of life, according to results from REMEDY-PILOT trial, presented at TCT 2026.
• HD-PCI: Higher Dose Heparin Does Not Show Appreciable Benefit Over Lower Dose During PCI
  Higher-dose unfractionated heparin (UFH) during PCI did not improve clinical outcomes vs. a lower-dose strategy, according to findings from the HD-PCI trial presented at TCT 2026.